Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTC-BB:NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample.  The eLab S1 is currently marketed and CE marked for use with a plasma sample.  The new authorization for a whole blood sample provides even faster results than the Company’s earlier plasma-based panel by eliminating the step of first centrifuging blood to produce a plasma sample.